Sensus Healthcare to Participate at H.C. Wainwright 23rd Annual Global Investment Conference

Boca Raton, Fla., Sept. 08, 2021 (GLOBE NEWSWIRE) —

Sensus Healthcare, Inc. (Nasdaq: SRTS

), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announced that Joe Sardano, chairman and chief executive officer, will present at the H.C. Wainwright 23

rd

Annual Global Investment Conference to be held virtually from September 13 – 15, 2021.

A webcast of the virtual presentation will be available starting at 7:00 am (EST) on Monday, September 13, 2021, and can be accessed through the Investors Relations section of Sensus Healthcare’s website at


www.sensushealthcare.com


or directly through the webcast


link


. An archived replay of the webcast will be available on the Company’s website after the conference.


About Sensus Healthcare

Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for both oncological and non-oncological conditions. The Sculptura™ modulated robotic brachytherapy radiation oncology system provides targeted directional anisotropic radiation therapy (ART) and brachytherapy utilizing our proprietary, state-of-the-art 3D Beam Sculpting™ to treat patients undergoing cancer treatment during surgery, or at the tumor site, fast and efficiently. Sensus also offers its proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its portfolio of innovative medical device products, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world.

For more information, visit


www.sensushealthcare.com


.


Contact:




LHA Investor Relations

Kim Sutton Golodetz

212-838-3777



[email protected]



Primary Logo